



Atty. Dkt. No. 057491/0413

#221  
(43)  
Dkt  
41283

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Desmond MASCARENHAS  
Title: NULL IGF FOR THE TREATMENT OF CANCER  
Appl. No.: 09/399,120  
Filing Date: 9/20/99  
Examiner: Anish GUPTA  
Art Unit: 1654

TECH CENTER 1600/2900

APR 09 2003

RECEIVED

RESPONSE UNDER 37 C.F.R. §1.116

Commissioner for Patents  
Washington, D.C. 20231

Sir:

This communication responds to a final office action dated November 5, 2002, concerning the above-referenced patent application. By virtue of the accompanying petition and payment of extension fees, the present deadline for response is April 7, 2003, since April 5, 2003 is a Saturday. No other fees are believed due, but the PTO is authorized to invoice account No. 190741 for any charges deemed necessary. Please amend the application as follows:

In the Claims:

Please cancel, without prejudice, claims 11-15 and 17 for being drawn to a non-elected invention.

Please add the following new claims:

45. (New) The method of claim 1, wherein said null IGF-I is selected from the group consisting of [Leu 60] IGF-I, [Ala31, Leu60] IGF-I; [Leu24, Leu60] IGF-I; [Leu24, Ala31, Leu60] IGF-I; [Leu24, 59, 60, Ala31] IGF-I; [1-27, Gly4, 38-70] IGF-I; [Ser24] IGF-I; [Leu24, 1-62] IGF-I and [1-29, gly, gly, gly, gly, 42-62] IGF-I.

46. (New) The method of claim 4, wherein said null IGF-I is selected from the group consisting of [Leu 60] IGF-I, [Ala31, Leu60] IGF-I; [Leu24, Leu60] IGF-I; [Leu24, Ala31, Leu60] IGF-I; [Leu24, 59, 60, Ala31] IGF-I; [1-27, Gly4, 38-70] IGF-I; [Ser24] IGF-I; [Leu24, 1-62] IGF-I and [1-29, gly, gly, gly, gly, 42-62] IGF-I.

04/08/2003 CNGUYEN 00000034 09399120 Add E!

01 FC:1202

36.00 DP